Literature DB >> 29627334

Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.

Jimme K Wiggers1, Bas Groot Koerkamp2, David van Klaveren3, Robert J Coelen4, C Yung Nio5, Peter J Allen6, Marc G Besselink4, Olivier R Busch4, Michael I D'Angelica6, Ronald P DeMatteo6, T Peter Kingham6, Thomas M van Gulik4, William R Jarnagin6.   

Abstract

BACKGROUND: Many patients with resectable perihilar cholangiocarcinoma (PHC) on imaging are diagnosed intraoperatively with occult metastatic or locally advanced disease, precluding a curative-intent resection. This study aimed to develop and validate a preoperative risk score. STUDY
DESIGN: Patients with resectable PHC on imaging who underwent operations in 2 high-volume centers (US and Europe) between 2000 and 2015 were included. Multivariable logistic regression analysis was used to develop the risk score. Cross-validation was used to validate the score, alternating the 2 centers as "training" and "testing" datasets.
RESULTS: Of 566 patients who underwent operations, 309 (55%) patients had a resection, and in 257 (45%) patients, a curative-intent resection was precluded due to distant metastasis (n = 151 [27%]) or locally advanced disease (n = 106 [19%]). Preoperative predictors included bilirubin >2 mg/dL, bile duct involvement on imaging, portal vein involvement on imaging (≥180 degrees), hepatic artery involvement on imaging (≥180 degrees), and suspicious lymph nodes on imaging. The new risk score (c-index 0.75 after cross-validation) provided significantly more accurate predictions than the Bismuth classification (c-index 0.62), Blumgart T-staging (c-index 0.67), and cTNM staging (c-index 0.68). The new risk score identified 4 risk groups for occult metastatic or locally advanced disease: low (14.7%), intermediate (29.5%), high (47.3%), and very high risk (81.3%). The preoperative score groups also predicted survival after operation, irrespective of intraoperative findings (p < 0.001).
CONCLUSIONS: The validated risk score can predict occult distant metastatic or locally advanced PHC based on 5 preoperatively available factors. The score can be useful in preoperative shared decision making and selection of patients in neoadjuvant clinical trials.
Copyright © 2018 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29627334      PMCID: PMC6089225          DOI: 10.1016/j.jamcollsurg.2018.03.041

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  26 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures.

Authors:  D Erdogan; J J Kloek; F J W ten Kate; E A J Rauws; O R C Busch; D J Gouma; T M van Gulik
Journal:  Br J Surg       Date:  2008-06       Impact factor: 6.939

3.  New staging system and a registry for perihilar cholangiocarcinoma.

Authors:  Michelle L Deoliveira; Richard D Schulick; Yuji Nimura; Charles Rosen; Gregory Gores; Peter Neuhaus; Pierre-Alain Clavien
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

4.  Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma.

Authors:  K M McMasters; T M Tuttle; S D Leach; T Rich; K R Cleary; D B Evans; S A Curley
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

5.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

6.  Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.

Authors:  Henrik Petrowsky; Peer Wildbrett; Daniela B Husarik; Thomas F Hany; Simona Tam; Wolfram Jochum; Pierre-Alain Clavien
Journal:  J Hepatol       Date:  2006-04-19       Impact factor: 25.083

Review 7.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

8.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02

Review 9.  Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.

Authors:  Jan Grendar; Petra Grendarova; Richie Sinha; Elijah Dixon
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

Review 10.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.

Authors:  E C Burke; W R Jarnagin; S N Hochwald; P W Pisters; Y Fong; L H Blumgart
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

View more
  5 in total

1.  Multidetector computed tomography assessment of vascular involvement in perihilar cholangiocarcinoma.

Authors:  Lotte C Franken; Robert J S Coelen; Joris I Erdmann; Joanne Verheij; Marnix P Kop; Thomas M van Gulik; Saffire S Phoa
Journal:  Quant Imaging Med Surg       Date:  2021-11

Review 2.  Preoperative Management of Perihilar Cholangiocarcinoma.

Authors:  Ryan J Ellis; Kevin C Soares; William R Jarnagin
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

3.  Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study.

Authors:  Hannes Jansson; Pim B Olthof; Annika Bergquist; Marjolein A P Ligthart; Silvio Nadalin; Roberto I Troisi; Bas Groot Koerkamp; Ruslan Alikhanov; Hauke Lang; Alfredo Guglielmi; Matteo Cescon; William R Jarnagin; Luca Aldrighetti; Thomas M van Gulik; Ernesto Sparrelid
Journal:  HPB (Oxford)       Date:  2021-04-28       Impact factor: 3.647

4.  Preoperative risk factors for early recurrence after resection of perihilar cholangiocarcinoma.

Authors:  Ryusei Yamamoto; Teiichi Sugiura; Ryo Ashida; Katsuhisa Ohgi; Mihoko Yamada; Shimpei Otsuka; Takeshi Aramaki; Koiku Asakura; Katsuhiko Uesaka
Journal:  BJS Open       Date:  2022-09-02

Review 5.  Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.

Authors:  Daniele Dondossola; Michele Ghidini; Francesco Grossi; Giorgio Rossi; Diego Foschi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.